A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-11
- Sponsors Eli Lilly and Company
- 08 Nov 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.
- 08 Nov 2019 This trial has been completed in Austria, according to European Clinical Trials Database.
- 26 Jun 2019 According to an Eli Lilly media release, this trial will continue through 52 weeks to evaluate longer-term safety data and is expected to complete in late 2019.Lilly plans to submit to regulatory authorities by late 2019 and will share detailed results at a future date.